Khurum H. Khan
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Apparent diffusion coefficient and kurtosis parameters show early response to anti-angiogenic therapy in patients with colorectal liver metastases.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: March 10, 2026
Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastases.
Journal: Cancer treatment reviews
Published: March 07, 2026
Editorial: Deciphering the inflammatory response in colorectal and ovarian cancers.
Journal: Frontiers in immunology
Published: February 21, 2026
ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy.
Journal: Frontiers in immunology
Published: November 03, 2025
Bevacizumab in biliary tract cancer: a clinical catalyst in the era of chemo-immunotherapy?
Journal: Journal of gastrointestinal oncology
Published: September 10, 2025
Is BEER the answer?-non-immunotherapeutic targeted maintenance treatment of chemotherapy-responsive advanced biliary tract cancers.
Journal: Translational gastroenterology and hepatology
Published: January 06, 2025
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.
Journal: BMC cancer
Published: November 26, 2024
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma.
Journal: Cancer treatment reviews
Published: October 02, 2024
Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm.
Journal: Cancer treatment reviews
Published: April 01, 2024
Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies.
Journal: Cancers
Published: December 23, 2023
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 16, 2023
Last Updated: 09/26/2026